Search Database

Name

Orgovyx

Alternate Names

Relugolix

Abbreviations

None

Category

Hormones and hormonal mechanisms

Subcategory

NSC Number

None

Primary Site

Prostate

Histology

None

Remarks

December 18, 2020 The FDA approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, (ORGOVYX) for adult patients with advanced prostate cancer.

Coding

This drug should be coded
Glossary